NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free OPRX Stock Alerts $11.12 -0.17 (-1.51%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$10.98▼$11.4150-Day Range$8.80▼$13.1752-Week Range$6.92▼$16.65Volume78,700 shsAverage Volume133,233 shsMarket Capitalization$203.16 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get OptimizeRx alerts: Email Address OptimizeRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside43.9% Upside$16.00 Price TargetShort InterestBearish5.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.42) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.74 out of 5 starsComputer And Technology Sector508th out of 575 stocksBusiness Services, Not Elsewhere Classified Industry82nd out of 90 stocks 3.4 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOptimizeRx has only been the subject of 3 research reports in the past 90 days.Read more about OptimizeRx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.73% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in OptimizeRx has recently increased by 12.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for OptimizeRx this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.42) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -10.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -10.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About OptimizeRx Stock (NASDAQ:OPRX)OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.Read More OPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Stock News HeadlinesJune 4, 2024 | americanbankingnews.comBrokerages Set OptimizeRx Co. (NASDAQ:OPRX) Price Target at $16.00June 4, 2024 | americanbankingnews.comOptimizeRx (NASDAQ:OPRX) and Western Union (NYSE:WU) Financial ContrastMay 15, 2024 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Reports First Quarter 2024 Financial ResultsMay 15, 2024 | marketwatch.comOptimizeRx Shares Rise 23% on 1Q Revenue Beat, FY GuidanceMay 15, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)May 15, 2024 | msn.comOptimizeRx Corporation (NASDAQ:OPRX) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comOptimizeRx Corp (OPRX) Q1 2024 Earnings Call Transcript Highlights: Surging Revenues and ...May 14, 2024 | investorplace.comOPRX Stock Earnings: OptimizeRx Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | globenewswire.comOptimizeRx Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comOptimizeRx to Participate in Upcoming Investor ConferencesApril 29, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for AbbVie: Future Growth Beyond Humira’s CompetitionApril 26, 2024 | globenewswire.comOptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ETApril 18, 2024 | globenewswire.comOptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) ReportApril 16, 2024 | globenewswire.comOptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsApril 13, 2024 | stockhouse.comOptimizeRx Named America's Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | finance.yahoo.comOptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | finance.yahoo.comOptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | globenewswire.comOptimizeRx Named America's Fastest-Growing Company for Fifth Year in a RowApril 6, 2024 | investorplace.com7 Top Undervalued Stocks Primed for a Multibagger RecoveryApril 4, 2024 | markets.businessinsider.comOptimizeRx: A Strong Buy on Strategic Acquisitions and Innovative Platform ExpansionApril 2, 2024 | au.lifestyle.yahoo.comTesla blames sales drop on Houthi attacks and arson in GermanyApril 1, 2024 | msn.comAriana Madix To Host ‘Love Island USA’ as Sarah Hyland Departs FranchiseApril 1, 2024 | au.news.yahoo.comCanoo spent double its annual revenue on the CEO’s private jet in 2023April 1, 2024 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 OPTIMIZERx Corp Earnings CallSee More Headlines Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/09/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees135Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+43.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-23.10% Pretax Margin-32.38% Return on Equity-6.96% Return on Assets-5.53% Debt Debt-to-Equity Ratio0.26 Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual Sales$71.52 million Price / Sales2.84 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book1.60Miscellaneous Outstanding Shares18,270,000Free Float17,466,000Market Cap$203.16 million OptionableOptionable Beta1.28 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. William J. Febbo (Age 55)CEO & Director Comp: $863.15kMr. Stephen L. Silvestro (Age 46)President Comp: $591.62kMr. Edward Stelmakh C.M.A. (Age 58)M.B.A., CFO & COO Comp: $626.74kMr. Andrew Jacob D'SilvaSenior Vice President of Corporate FinanceKey CompetitorsLimelight NetworksNASDAQ:LLNWConduentNASDAQ:CNDTOLONYSE:OLOViadNYSE:VVIXometryNASDAQ:XMTRView All CompetitorsInsiders & InstitutionsAWM Investment Company Inc.Bought 33,000 shares on 5/16/2024Ownership: 4.692%Kennedy Capital Management LLCSold 170,886 shares on 5/16/2024Ownership: 1.759%First Light Asset Management LLCBought 10,286 shares on 5/15/2024Ownership: 9.558%Hillsdale Investment Management Inc.Sold 5,000 shares on 5/11/2024Ownership: 0.059%Vanguard Group Inc.Bought 6,291 shares on 5/10/2024Ownership: 5.649%View All Insider TransactionsView All Institutional Transactions OPRX Stock Analysis - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price target for 2024? 7 Wall Street analysts have issued 12 month target prices for OptimizeRx's shares. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 43.9% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2024? OptimizeRx's stock was trading at $14.31 on January 1st, 2024. Since then, OPRX shares have decreased by 22.3% and is now trading at $11.12. View the best growth stocks for 2024 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) released its earnings results on Tuesday, May, 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.16. The company earned $19.69 million during the quarter, compared to analysts' expectations of $18.66 million. OptimizeRx had a negative net margin of 23.10% and a negative trailing twelve-month return on equity of 6.96%. During the same period last year, the company posted ($0.34) EPS. What ETF holds OptimizeRx's stock? Jacob Forward ETF holds 10,785 shares of OPRX stock, representing 4.87% of its portfolio. What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $104.7 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by a number of retail and institutional investors. Top institutional investors include First Light Asset Management LLC (9.56%), Vanguard Group Inc. (5.65%), AWM Investment Company Inc. (4.69%), Blair William & Co. IL (4.30%), Rice Hall James & Associates LLC (2.21%) and Kennedy Capital Management LLC (1.76%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPRX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.